Good news! Amazing stuff! Cancer is history (soon)!
So Prozac junkies are cancer free? Just kidding!
When you type Prozac into Google search the first search result is "Help is available ... 988 Suicide & Crisis Lifeline"
"Key takeaways
- SSRIs boosted the ability of T cells to kill cancer cells and suppressed tumor growth in both mouse and human tumor models.
- Researchers also tested a combination of an SSRI and an anti-PD-1 antibody, a common immune checkpoint blockade therapy. Together, the drugs drastically reduced tumor size and even led to complete remission in some mouse models of melanoma and colon cancer.
- Repurposing existing FDA-approved drugs like SSRIs could speed up the process of bringing new cancer treatments to patients, the researchers said.
... Selective serotonin reuptake inhibitors, or SSRIs, significantly enhanced the ability of T cells to fight cancer and suppressed tumor growth across a range of cancer types in both mouse and human tumor models ...
The researchers tested SSRIs in mouse and human tumor models representing melanoma, breast, prostate, colon and bladder cancer. They found that SSRI treatment reduced average tumor size by over 50% and made the cancer-fighting T cells, known as killer T cells, more effective at killing cancer cells. ..."
From the highlights and abstract:
"Highlights
• SERT acts as an immune checkpoint restricting CD8 T cell antitumor immunity
• SERT inhibits CD8 T cell antitumor responses by depleting intratumoral serotonin
• SSRIs suppress multiple solid tumors and synergize with anti-PD-1 in mice
•SERT upregulates in TEMRA, and its intratumoral expression links to poor patient survival
Summary
Identifying additional immune checkpoints hindering antitumor T cell responses is key to the development of next-generation cancer immunotherapies. Here, we report the induction of serotonin transporter (SERT), a regulator of serotonin levels and physiological functions in the brain and peripheral tissues, in tumor-infiltrating CD8 T cells.
Inhibition of SERT using selective serotonin reuptake inhibitors (SSRIs), the most widely prescribed antidepressants, significantly suppressed tumor growth and enhanced T cell antitumor immunity in various mouse syngeneic and human xenograft tumor models.
Importantly, SSRI treatment exhibited significant therapeutic synergy with programmed cell death protein 1 (PD-1) blockade, and clinical data correlation studies negatively associated intratumoral SERT expression with patient survival in a range of cancers.
Mechanistically, SERT functions as a negative-feedback regulator inhibiting CD8 T cell reactivities by depleting intratumoral T cell-autocrine serotonin. These findings highlight the significance of the intratumoral serotonin axis and identify SERT as an immune checkpoint, positioning SSRIs as promising candidates for cancer immunotherapy."
Serotonin transporter inhibits antitumor immunity through regulating the intratumoral serotonin axis (open access)
Graphical abstract
No comments:
Post a Comment